The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Merck (NYSE:MRK) said the FDA has granted Breakthrough Therapy designation for its antibody drug conjugate sacituzumab ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...